NASDAQ: PULMPulmatrix Inc Stock
$6.01+0.02 (+0.33%)
Updated Jan 10, 2025
PULM Price
$6.01
Fair Value Price
N/A
Market Cap
$21.95M
52 Week Low
$1.55
52 Week High
$8.44
P/E
-2.28x
P/B
2.01x
P/S
0.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.01M
Earnings
-$9.66M
Gross Margin
100%
Operating Margin
-96.51%
Profit Margin
-96.5%
Debt to Equity
0.05
Operating Cash Flow
-$11M
Beta
0.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PULM Overview
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PULM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
B
Momentum
C
Sentiment
D
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PULM
Ranked#120 of 556
Ranked#120 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.25 | A | |
| $121.41 | A | |
| $5.27 | A |
Be the first to know about important PULM news, forecast changes, insider trades & much more!
PULM News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PULM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PULM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PULM is good value based on its book value relative to its share price (2.01x), compared to the US Biotechnology industry average (4.88x)
P/B vs Industry Valuation
PULM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PULM due diligence checks available for Premium users.
Valuation
PULM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.28x
Industry
-113.93x
Market
30.06x
PULM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
4.88x
PULM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PULM's financial health
Profit margin
Revenue
$366.0k
Net Income
-$2.6M
Profit Margin
-706.8%
PULM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PULM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.5M
Liabilities
$590.0k
Debt to equity
0.05
PULM's short-term assets ($11.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PULM's short-term assets ($11.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PULM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PULM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$0.0
PULM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PULM vs Biotech Stocks
Pulmatrix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.